- ResMed files patent infringement actions against Fisher &
Paykel Healthcare in U.S., German and New
Zealand courts and in the U.S. International Trade
Commission
- German court stops the sale of F&P Simplus, Eson and Eson
2 masks
- ResMed asks court to declare F&P patents invalid or not
infringed
SAN DIEGO, Aug. 17, 2016 /PRNewswire/ -- ResMed (NYSE:
RMD), the world's leading tech-driven medical device company and
innovator in sleep-disordered breathing and respiratory care,
announced today it has filed legal actions with the United States
International Trade Commission, the United States District Court
for the Southern District of California in San
Diego (3:16-cv-02072-JAH-MDD), as well as courts in
New Zealand and Germany, to stop the infringement of its
patented technology by New
Zealand-based medical device manufacturer Fisher &
Paykel Healthcare.
"ResMed is known for its commitment to providing patients with
high-quality products that result from sustained, substantial
investment in research and development and a focus on each user's
needs," said ResMed global general counsel and chief administrative
officer David Pendarvis. "ResMed's
proprietary designs and superior innovative technologies reflect
these priorities."
"We remain steadfast in our commitment to defend our
intellectual property wherever necessary to ensure patients receive
the high-quality care they deserve. We are confident that when the
courts hear all the evidence, ResMed will prevail on its case and
defeat any claims asserted by Fisher & Paykel."
In the U.S. International Trade Commission, ResMed seeks an
injunction banning importation of Fisher & Paykel Simplus full
face mask, Eson nasal mask and Eson 2 nasal mask. In the U.S.
District Court for the Southern District of California, ResMed asserts that Fisher &
Paykel Healthcare's Simplus full face mask, Eson nasal mask and
Eson 2 nasal mask infringe ResMed's patents relating to modular
mask systems, headgear design, and cushion design. ResMed also
asked the San Diego court to
invalidate patents that Fisher & Paykel recently asserted
against ResMed, to declare that ResMed does not infringe those
patents, or both.
ResMed has also initiated preliminary injunction proceedings in
Germany, and a suit in
New Zealand, to stop infringement
in those countries. In the German proceedings, the District Court
in Munich has already entered two
preliminary injunctions to stop the sale of Simplus, Eson and Eson
2 masks in Germany based on
infringement of German parts of two of ResMed´s European patents.
In New Zealand, ResMed is asking
an Auckland court to stop Fisher
& Paykel from manufacturing and exporting infringing masks from
that country.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 2 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
Contacts:
|
|
For News
Media:
|
For
Investors:
|
Alison
Graves
|
Agnes Lee
|
Global Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/resmed-takes-fisher--paykel-to-court-over-patents-300315090.html
SOURCE ResMed Inc.